Regulatory Approval

30 June 2008


                           ECO Animal Health Group plc
                             (formerly Lawrence plc)


                  New Aivlosin®  approval for poultry in Europe


ECO  Animal  Health  Group plc is pleased to announce that  its  subsidiary  Eco
Animal Health Limited (ECO) has been granted a marketing authorisation from  the
European  Commission  for  Aivlosin® granules for oral solution.  The  Aivlosin®
granules  dissolve  readily  in drinking water thus enabling  the  accurate  and
simultaneous treatment of large numbers of chickens.

This  marketing authorisation allows Aivlosin® to be marketed in Europe for  the
treatment  and  prevention of mycoplasmal respiratory  disease  in  chickens,  a
segment  estimated to be worth in the region of US $18 million  at  manufacturer
level.

ECO  is  targeting  a  significant share of this market segment  and  will  sell
directly  in  the two major EU poultry producing markets of France and  the  UK.
Several  national distributors, selected for their local market knowledge,  have
been appointed in other EU territories.

The  European Commission's granting of this marketing authorisation  is  another
important  step  in  ECO's  continuing development of  Aivlosin®,  its  patented
macrolide antibiotic. The authorisation will further extend the marketing  reach
of  Aivlosin®  as  a  global  veterinary  product  used  for  the  treatment  of
respiratory and enteric diseases in pigs and poultry.


Contacts:
ECO  Animal Health Group plc                           Marc Loomes     020  8447
8899

Spiro Financial                              Anthony Spiro      020 8336 6196

Cenkos  Securities plc                                      Stephen  Keys    020
7397 8926
(Nominated    Adviser)                                                 Elizabeth
Bowman  020 7397 8928

ECO  Animal  Health Group plc is a leader in the development,  registration  and
marketing of pharmaceutical products for animals. Our products for these  global
growth markets promote well-being. Our financial goals are achieved through  the
careful  and  responsible  application of science  to  generate  value  for  our
shareholders.